Analytical Method Development and Validation for Elagolix and its Related Substances: A Comprehensive Review

https://doi.org/10.61096/ijpir.v16.iss4.2026.1092-1105

Authors

  • Samyuktha Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India
  • P. Vivek Sagar Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India
  • J. Sunayana Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India
  • S. Muni Sirisha Department of Pharmaceutical Analysis, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.), Tarnaka, Secunderabad, Telangana, India

Keywords:

Elagolix sodium, related substances, stability-indicating method, RP-HPLC, UHPLC, forced degradation, quality by design, ICH Q2(R2)

Abstract

Elagolix sodium is the first orally active, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, approved by the US FDA in 2018 for moderate to severe endometriosis-associated pain (Orilissa® tablets, 150 and 200 mg) and later in combination with estradiol and norethindrone acetate for heavy menstrual bleeding due to uterine fibroids (Oriahnn® capsules). Its uracil core carries a secondary-amine, butanoic-acid side chain, a chiral centre and hindered biaryl rotation, which together give a varied impurity profile of process intermediates, the S-enantiomer, atropisomers, oxidative and cyclised (δ-lactam) degradants, potential N-nitroso derivatives and alkyl-phosphate genotoxic impurities.

This review surveys the analytical methods published for elagolix between 2020 and 2026. It covers RP-HPLC assay methods, stability-indicating related-substances methods by HPLC and UHPLC, chiral and atropisomer separations, LC-MS/MS methods for genotoxic impurities and plasma, structural elucidation of degradation products, spectrofluorimetric methods, and a method for the fixed-dose combination. For each, the chromatographic conditions, validation findings and limitations are summarised.

Although several related-substances methods now exist, they disagree on degradation behaviour (alkaline lability), use long runs (46–75 min) or extreme pH, rarely quantify identified degradants against reference standards, and none is pharmacopoeial or validated under ICH Q2(R2)/Q14. N-nitroso elagolix and atropisomer control remain largely unaddressed. A strategy for a robust, MS-compatible, stability-indicating method is proposed.

Dimensions

Published

2026-11-13

How to Cite

1.
Samyuktha, P. Vivek Sagar, J. Sunayana, S. Muni Sirisha. Analytical Method Development and Validation for Elagolix and its Related Substances: A Comprehensive Review. Int J Pharm Ind Res [Internet]. 2026 Nov. 13 [cited 2026 Nov. 17];16(4):1092-105. Available from: https://www.ijpir.com/index.php/ijpir/article/view/835

Issue

Section

Articles